drugset / Trial / NCT06514742

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742 ↗

Phase 3 Terminated 101 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have not responded well to current antidepressant therapy with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI).

Timeline

Start
2024-06-26
Primary completion
2025-04-08
Completion
2025-04-24

Outcome

Outcome not reported

Stopped: “Early study termination due to insufficient efficacy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Aticaprant Small molecule 10 mg Oral